Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroup B Invasive Meningococcal Disease
Stefan Scholz(Robert Koch Institute), Wolfgang Greiner(Bielefeld University), Kinga Meszaros(GlaxoSmithKline (Belgium)), Ekkehard Beck(GlaxoSmithKline (Belgium)), Melanie Schneider(MorphoSys (Germany)), Magdalena Schwarz(Austrian Breast & Colorectal Cancer Study Group), B. Ultsch(Robert Koch Institute)
Cited by 19
Related Papers
Barriers and Strategies in Guideline Implementation—A Scoping Review
|Healthcare|2016|946
Development of the EQ-5D-Y: a child-friendly version of the EQ-5D
|Quality of Life Research|2010|903
German Value Set for the EQ-5D-5L
|PharmacoEconomics|2018|618
Feasibility, reliability, and validity of the EQ-5D-Y: results from a multinational study
|Quality of Life Research|2010|476
A single European currency for EQ-5D health states
|The European Journal of Health Economics|2003|465